Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-690514 vs Erlotinib in Previously Treated NSCLC
NCT00743938Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2009
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of BMS-690514 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-Free Survival at 36 weeks. Started Mar 2009; status: completed.
02
Drugs
BMS-690514
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00743938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00743938.